Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Thank you for standing by. My name is Prila, and I will be your conference operator today. At this time, I would like to welcome everyone ...

UX and UI designers work closely with engineers throughout product development to build and implement design concepts and ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

Kinross Gold reported increased adjusted net earnings and a record free cash flow in 2024, as the company works toward proceeding with mining at the Redbird open pit at the ...